Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety

This phase 2 study assessed the safety, pharmacokinetics, pharmacodynamics and efficacy of carfilzomib, a selective proteasome inhibitor, in patients with multiple myeloma and varying degrees of renal impairment, including patients on chronic hemodialysis. Patients were grouped by creatinine clearan...

Descripción completa

Detalles Bibliográficos
Autores principales: Badros, A Z, Vij, R, Martin, T, Zonder, J A, Kunkel, L, Wang, Z, Lee, S, Wong, A F, Niesvizky, R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3740399/
https://www.ncbi.nlm.nih.gov/pubmed/23364621
http://dx.doi.org/10.1038/leu.2013.29

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3740399/
https://www.ncbi.nlm.nih.gov/pubmed/23364621
http://dx.doi.org/10.1038/leu.2013.29

Ejemplares similares